ImaRx to cut staff

ImaRx says it will immediately cut its workforce after scrapping a planned deal to sell its urokinase inventory and related assets to Microbix Biosystems for $17 million. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.